Results 311 to 320 of about 7,150,903 (384)

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

open access: yesMolecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz   +15 more
wiley   +1 more source

Navigating the Challenges: A Commentary on Barriers to Autism Screening in Childcare Centers. [PDF]

open access: yesBehav Sci (Basel)
Wieckowski AT   +6 more
europepmc   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

open access: yesMolecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed   +10 more
wiley   +1 more source

Identification of Sarcopenic Obesity by Fat-to-Muscle Ratio in Older Adults: A Cohort Study. [PDF]

open access: yesJ Cachexia Sarcopenia Muscle
Kakita D   +7 more
europepmc   +1 more source

Methods and mechanisms for measuring and monitoring outcomes from newborn bloodspot screening: a scoping review.

open access: yesHealth Technol Assess
Scandrett K   +12 more
europepmc   +1 more source

Cost-Effectiveness of Home-Based Self-Sampling vs Clinician Sampling for Anal Precancer Screening.

open access: yesJAMA Netw Open
Damgacioglu H   +10 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy